Nagy J A, Masse E M, Herzberg K T, Meyers M S, Yeo K T, Yeo T K, Sioussat T M, Dvorak H F
Department of Pathology, Beth Israel Hospital, Boston, Massachusetts 02215.
Cancer Res. 1995 Jan 15;55(2):360-8.
Previous studies have shown that accumulation of tumor ascites fluid results in large part from increased permeability of peritoneal lining vessels (Nagy et al., Cancer Res., 49: 5449-5458, 1989; Nagy et al., Cancer Res., 53: 2631-2643, 1993). However, the specific microvessels rendered hyperpermeable have not been identified nor has the basis of peritoneal vascular hyperpermeability been established. To address these questions, TA3/St and MOT carcinomas, well-characterized transplantable murine tumors that grow in both solid and ascites form, were studied as model systems. Ascites tumor cells of either type were injected i.p. into syngeneic A/Jax and C3Heb/FeJ mice, and ascites fluid and plasma were collected at intervals thereafter up to 8 and 28 days, respectively. Beginning several days after tumor cell injection, small blood vessels located in tissues lining the peritoneal cavity (mesentery, peritoneal wall, and diaphragm) became hyperpermeable to several macromolecular tracers (125I-human serum albumin, FITC-dextran, colloidal carbon, and Monastral Blue B). Increased microvascular permeability correlated with the appearance in ascites fluid of vascular permeability factor (VPF), a tumor cell-secreted mediator that potently enhances vascular permeability to circulating macromolecules. VPF was measured in peritoneal fluid by both a functional bioassay and a sensitive immunofluorometric assay. The VPF concentration, total peritoneal VPF, ascites fluid volume, tumor cell number, and hyperpermeability of peritoneal lining microvessels were found to increase in parallel over time. The close correlation of peritoneal fluid VPF concentration with the development of hyperpermeable peritoneal microvessels in these two well-defined ascites tumors suggests that VPF secretion by tumor cells is responsible, in whole or in part, for initiating and maintaining the ascites pattern of tumor growth.
先前的研究表明,肿瘤腹水的积聚在很大程度上是由于腹膜衬里血管通透性增加所致(纳吉等人,《癌症研究》,49: 5449 - 5458,1989;纳吉等人,《癌症研究》,53: 2631 - 2643,1993)。然而,尚未确定导致通透性增加的具体微血管,也未明确腹膜血管通透性增加的原因。为了解决这些问题,我们以TA3/St和MOT癌作为模型系统进行研究,这两种癌是特征明确的可移植性小鼠肿瘤,既能以实体瘤形式生长,也能以腹水形式生长。将这两种类型的腹水肿瘤细胞腹腔注射到同基因的A/Jax和C3Heb/FeJ小鼠体内,此后分别在长达8天和28天的时间间隔内收集腹水和血浆。在肿瘤细胞注射几天后,位于腹膜腔衬里组织(肠系膜、腹膜壁和膈肌)中的小血管对几种大分子示踪剂(125I - 人血清白蛋白、异硫氰酸荧光素 - 葡聚糖、胶体碳和酸性媒介蓝B)的通透性增加。微血管通透性增加与腹水液中血管通透性因子(VPF)的出现相关,VPF是一种肿瘤细胞分泌的介质,能显著增强血管对循环大分子的通透性。通过功能性生物测定法和灵敏的免疫荧光测定法对腹膜液中的VPF进行了测量。发现VPF浓度、腹膜总VPF、腹水液体积、肿瘤细胞数量以及腹膜衬里微血管的通透性随时间平行增加。在这两种明确的腹水肿瘤中,腹膜液VPF浓度与高通透性腹膜微血管的发展密切相关,这表明肿瘤细胞分泌的VPF全部或部分地负责启动和维持肿瘤生长的腹水模式。